You just read:

European Neurologists Expect Significant Increases in the Use of Both Tysabri and Extavia in Their Multiple Sclerosis Patients the Next Six Months, According to a Recent Report From BioTrends

News provided by

BioTrends Research Group, Inc.

Dec 21, 2010, 10:15 ET